Compare 10X Genomics Inc (TXG) vs Victoria's Secret & Co (VSXY) Price & Performance

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.

Victoria's Secret (VSXY) trades at $87.09, up 6.92% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows improving fundamentals with revenue stabilizing at $6.23B in 2025 and net income recovering to $165M. Analyst consensus is bullish with a $88.56 price target, and institutional interest is growing, evidenced by Bessemer Group's increased stake in Q1 2026.

The outlook remains positive driven by international expansion, particularly in China, and product innovation. Risks include competitive pressures in retail and margin volatility. With no sell ratings from analysts and strong shareholder support for management, VSXY presents a growth opportunity, though investors should monitor execution on guidance and macroeconomic impacts on consumer spending.